A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

An Open Label Study to Evaluate the Effect on Bone Mineral Density, and the Safety, of Quarterly Intravenous Bonviva in Patients With Post-menopausal Osteoporosis.

Status

NO_LONGER_AVAILABLE

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT00493532

Enrollment

Unknown

Registered

2007-06-28

Start date

2007-06-30

Completion date

2010-12-31

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Osteoporosis

Brief summary

This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100 individuals.

Interventions

DRUGibandronate [Bonviva/Boniva]

3mg iv every 3 months

Eligibility

Sex/Gender

FEMALE

Age

No minimum to 80 Years

Healthy volunteers

Inclusion criteria

* post-menopausal women with osteoporosis; * \<=80 years of age; * naive to oral bisphosphonates, or have discontinued daily and/or weekly bisphosphonate treatment for \>1 year.

Exclusion criteria

* metabolic bone disease other than post-menopausal osteoporosis; * treatment with other drugs affecting bone metabolism within last 6 months; * previous or current malignant disease (except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer).

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026